electroCore’s Truvaga™ Now Works with the Apple Health app
electroCore (NASDAQ: ECOR) has announced that its wellness product Truvaga Plus, a hand-held vagus nerve stimulator, is now compatible with the Apple Health app. The integration allows users to track their mental wellbeing data alongside other health metrics in one consolidated platform.
Through the State of Mind API, users can log and monitor their emotional state after each Truvaga Plus session within the Health app's Mental Wellbeing category. Truvaga Plus is designed to provide stress relief, improve sleep, enhance peace of mind, and boost focus through gentle vagus nerve activation.
electroCore (NASDAQ: ECOR) ha annunciato che il suo prodotto per il benessere Truvaga Plus, uno stimolatore portatile del nervo vago, è ora compatibile con l'app Apple Health. Questa integrazione consente agli utenti di monitorare i dati sul loro benessere mentale insieme ad altri parametri di salute in un'unica piattaforma consolidata.
Attraverso la State of Mind API, gli utenti possono registrare e controllare il loro stato emotivo dopo ogni sessione con Truvaga Plus all'interno della categoria Benessere Mentale dell'app Health. Truvaga Plus è progettato per alleviare lo stress, migliorare il sonno, favorire la serenità e aumentare la concentrazione tramite una delicata attivazione del nervo vago.
electroCore (NASDAQ: ECOR) ha anunciado que su producto de bienestar Truvaga Plus, un estimulador portátil del nervio vago, ahora es compatible con la app Apple Health. La integración permite a los usuarios registrar sus datos de bienestar mental junto con otras métricas de salud en una plataforma consolidada.
A través de la API State of Mind, los usuarios pueden registrar y monitorear su estado emocional después de cada sesión con Truvaga Plus dentro de la categoría Bienestar Mental de la app Health. Truvaga Plus está diseñado para aliviar el estrés, mejorar el sueño, aumentar la tranquilidad y potenciar la concentración mediante una suave activación del nervio vago.
electroCore (NASDAQ: ECOR)는 휴대용 미주신경 자극기인 웰니스 제품 Truvaga Plus가 이제 Apple Health 앱과 호환된다고 발표했습니다. 이 통합을 통해 사용자는 정신 건강 데이터를 다른 건강 지표와 함께 하나의 통합 플랫폼에서 추적할 수 있습니다.
State of Mind API를 통해 사용자는 Health 앱의 정신 건강 카테고리 내에서 Truvaga Plus 세션 후 자신의 감정 상태를 기록하고 모니터링할 수 있습니다. Truvaga Plus는 부드러운 미주신경 자극을 통해 스트레스 완화, 수면 개선, 마음의 평화 증진, 집중력 향상을 목표로 설계되었습니다.
electroCore (NASDAQ : ECOR) a annoncé que son produit bien-être Truvaga Plus, un stimulateur portatif du nerf vague, est désormais compatible avec l'application Apple Health. Cette intégration permet aux utilisateurs de suivre leurs données de bien-être mental ainsi que d'autres indicateurs de santé sur une plateforme unifiée.
Grâce à l'API State of Mind, les utilisateurs peuvent enregistrer et suivre leur état émotionnel après chaque séance avec Truvaga Plus dans la catégorie Bien-être mental de l'application Health. Truvaga Plus est conçu pour soulager le stress, améliorer le sommeil, favoriser la sérénité et renforcer la concentration grâce à une activation douce du nerf vague.
electroCore (NASDAQ: ECOR) hat bekannt gegeben, dass sein Wellness-Produkt Truvaga Plus, ein tragbarer Vagusnerv-Stimulator, nun mit der Apple Health App kompatibel ist. Die Integration ermöglicht es Nutzern, ihre mentalen Wohlbefindensdaten zusammen mit anderen Gesundheitsmetriken in einer konsolidierten Plattform zu verfolgen.
Über die State of Mind API können Nutzer nach jeder Truvaga Plus-Sitzung ihren emotionalen Zustand in der Kategorie Mentales Wohlbefinden der Health App protokollieren und überwachen. Truvaga Plus wurde entwickelt, um Stress abzubauen, den Schlaf zu verbessern, innere Ruhe zu fördern und die Konzentration durch sanfte Stimulation des Vagusnervs zu steigern.
- Integration with Apple Health app expands product functionality and user experience
- Enhanced data tracking capabilities for users through State of Mind API
- Potential for broader market reach through Apple ecosystem
- None.
ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app.
Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relief, improve sleep, enhance peace of mind and improve focus.
Danielle Jones, Sr. Director of Direct-to-Consumer Marketing at electroCore, commented, “Using Truvaga Plus with the Apple Health app on the iPhone empowers you to better manage your health. You will see a consolidated view of all your health data, including data from Truvaga Plus, so you can track your progress in one convenient place. We are looking forward to continuing the development efforts of Truvaga Plus that will support our customers’ long-term experience.”
As users complete a session in the Truvaga Plus app, they will be able to log how they’re feeling. Using the State of Mind API, users can monitor how they’re feeling over time in the Health app in the Mental Wellbeing category. The Health app on the iPhone and the iPad is a central and secure place to store important health information and make it easy to access.
The app was developed to be used with the powerful privacy features on every iPhone that give users control over their data and who it is shared with.
About electroCore, Inc.
electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects, including integrating Truvaga Plus with the Apple Health application, new and existing wellness product offerings, and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments including focus group study results; the Company’s business prospects in the United States (including its e-commerce initiatives) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the ability to successfully launch and commercialize Truvaga Plus, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
